394 related articles for article (PubMed ID: 31077311)
1. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
Lamarca A; Ross P; Wasan HS; Hubner RA; McNamara MG; Lopes A; Manoharan P; Palmer D; Bridgewater J; Valle JW
J Natl Cancer Inst; 2020 Feb; 112(2):200-210. PubMed ID: 31077311
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
[TBL] [Abstract][Full Text] [Related]
3. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW
J Hepatol; 2020 Nov; 73(5):1109-1117. PubMed ID: 32446715
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
Valle JW; Furuse J; Jitlal M; Beare S; Mizuno N; Wasan H; Bridgewater J; Okusaka T
Ann Oncol; 2014 Feb; 25(2):391-8. PubMed ID: 24351397
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.
Bridgewater J; Lopes A; Wasan H; Malka D; Jensen L; Okusaka T; Knox J; Wagner D; Cunningham D; Shannon J; Goldstein D; Moehler M; Bekaii-Saab T; McNamara MG; Valle JW
Ann Oncol; 2016 Jan; 27(1):134-40. PubMed ID: 26483051
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma.
Franssen S; Holster JJ; Jolissaint JS; Nooijen LE; Cercek A; D'Angelica MI; Homs MYV; Wei AC; Balachandran VP; Drebin JA; Harding JJ; Kemeny NE; Kingham TP; Klümpen HJ; Mostert B; Swijnenburg RJ; Soares KC; Jarnagin WR; Groot Koerkamp B
Ann Surg Oncol; 2024 Jan; 31(1):115-124. PubMed ID: 37814188
[TBL] [Abstract][Full Text] [Related]
7. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
8. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study.
Strijker M; Belkouz A; van der Geest LG; van Gulik TM; van Hooft JE; de Meijer VE; Haj Mohammad N; de Reuver PR; Verheij J; de Vos-Geelen J; Wilmink JW; Groot Koerkamp B; Klümpen HJ; Besselink MG;
Acta Oncol; 2019 Jul; 58(7):1048-1055. PubMed ID: 30907207
[No Abstract] [Full Text] [Related]
9. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.
Lurje G; Bednarsch J; Czigany Z; Lurje I; Schlebusch IK; Boecker J; Meister FA; Tacke F; Roderburg C; Den Dulk M; Gaisa NT; Bruners P; Neumann UP
Eur J Surg Oncol; 2019 Aug; 45(8):1468-1478. PubMed ID: 31053477
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
Lowery MA; Goff LW; Keenan BP; Jordan E; Wang R; Bocobo AG; Chou JF; O'Reilly EM; Harding JJ; Kemeny N; Capanu M; Griffin AC; McGuire J; Venook AP; Abou-Alfa GK; Kelley RK
Cancer; 2019 Dec; 125(24):4426-4434. PubMed ID: 31454426
[TBL] [Abstract][Full Text] [Related]
11. Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis.
Reames BN; Bagante F; Ejaz A; Spolverato G; Ruzzenente A; Weiss M; Alexandrescu S; Marques HP; Aldrighetti L; Maithel SK; Pulitano C; Bauer TW; Shen F; Poultsides GA; Soubrane O; Martel G; Koerkamp BG; Guglielmi A; Itaru E; Pawlik TM
HPB (Oxford); 2017 Oct; 19(10):901-909. PubMed ID: 28728891
[TBL] [Abstract][Full Text] [Related]
12. Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma.
Sebastian NT; Tan Y; Miller ED; Williams TM; Noonan AM; Hays JL; Abdel-Misih S; Diaz DA
JAMA Netw Open; 2019 Sep; 2(9):e1911154. PubMed ID: 31517963
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma.
Madzikatire TB; Heng S; Gu H; Shan Y; Lin E; Banda J; Debora A; Madziva BA; Bowa MJ; Mudhuri MG; Bwalya C
Front Immunol; 2024; 15():1390887. PubMed ID: 38846939
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
Edeline J; Bridgewater J; Campillo-Gimenez B; Neveu E; Phelip JM; Neuzillet C; Boudjema K; Rolland Y; Valle JW; Garin E; Malka D; Lamarca A
Hepatology; 2024 Jan; 79(1):96-106. PubMed ID: 37505216
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, Risk Factors, and Survival of Patients with Intrahepatic Cholangiocarcinoma.
Chinchilla-López P; Aguilar-Olivos NE; García-Gómez J; Hernández-Alejandro KK; Chablé-Montero F; Motola-Kuba D; Patel T; Méndez-Sánchez N
Ann Hepatol; 2017; 16(4):565-568. PubMed ID: 28611259
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma.
Ahmed O; Yu Q; Patel M; Hwang G; Pillai A; Liao CY; Fung J; Baker T
J Vasc Interv Radiol; 2023 Apr; 34(4):702-709. PubMed ID: 36521794
[TBL] [Abstract][Full Text] [Related]
17. Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis.
Rahnemai-Azar AA; Weisbrod A; Dillhoff M; Schmidt C; Pawlik TM
Surg Oncol; 2017 Jun; 26(2):125-137. PubMed ID: 28577718
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
19. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.
Li T; Qin LX; Zhou J; Sun HC; Qiu SJ; Ye QH; Wang L; Tang ZY; Fan J
Liver Int; 2014 Jul; 34(6):953-60. PubMed ID: 24134199
[TBL] [Abstract][Full Text] [Related]
20. Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis.
Zhou PY; Tang Z; Liu WR; Tian MX; Jin L; Jiang XF; Wang H; Tao CY; Ding ZB; Peng YF; Qiu SJ; Dai Z; Zhou J; Fan J; Shi YH
BMC Cancer; 2017 Nov; 17(1):762. PubMed ID: 29137600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
